All IndicationsNeurology & CNSPhase 2Phase 2Phase 2Phase 2Phase 2
🧠
Parkinson Disease
5
Companies
5
Drug Programs
0
Phase 3
0
Upcoming PDUFAs
Competitors
ALTHX.PA
Theranexus SA
THN102 Dosage A
HRTIS.HE
Herantis Pharma Oyj
Cerebral Dopamine Neurotrophic Factor
DNLI
Denali Therapeutics Inc.
BIIB122 225 mg
ITCI
Intra-Cellular Therapies, Inc.
Lenrispodun
JAZZ
Jazz Pharmaceuticals plc
Suvecaltamide
| Company | Drug | Phase | Designations | Timeline | Trial ID |
|---|---|---|---|---|---|
| ALTHX.PA Theranexus SA | THN102 Dosage A | Phase 2 | — | — | — |
| HRTIS.HE Herantis Pharma Oyj | Cerebral Dopamine Neurotrophic Factor | Phase 2 | — | — | — |
| DNLI Denali Therapeutics Inc. | BIIB122 225 mg | Phase 2 | — | — | — |
| ITCI Intra-Cellular Therapies, Inc. | Lenrispodun | Phase 2 | — | — | — |
| JAZZ Jazz Pharmaceuticals plc | Suvecaltamide | Phase 2 | — | — | — |
Development Stage Distribution
Phase 2
5
PDUFA Timeline
No upcoming PDUFA dates for this indication.
Not financial advice
Signals are probabilistic and based on historical data — past performance doesn't guarantee future results. Do your own research.